Lead Product(s) : Aminolevulinic Acid Hexylester
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Asieris Announces NDA Acceptance for Regulatory Review of Cevira in China
Details : APL-1702 (cevira) is a photodynamic drug-device combination product in development for the non-surgical treatment of high-grade squamous intraepithelial lesions, licensed to Asieris by Photocure.
Product Name : Cevira
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 05, 2024
Lead Product(s) : Aminolevulinic Acid Hexylester
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Aminolevulinic Acid Hexylester
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Asieris has received Clinical Trial Approval from China NMPA for the global, multi-centered Phase III clinical trial of its photodynamic drug-device combination product Cevira®, which is being developed for the non-surgical treatment of high-grade cerv...
Product Name : Cevira
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 07, 2020
Lead Product(s) : Aminolevulinic Acid Hexylester
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable